The University of Southampton
University of Southampton Institutional Repository

The therapeutic use of antibodies for malignancy

The therapeutic use of antibodies for malignancy
The therapeutic use of antibodies for malignancy
The idea of using the specificity of antibodies to target malignant cells was put forward very soon after the discovery of techniques to generate monoclonal reagents. The responses seen with mouse anti-idiotype in patients with B-cell lymphomas indicated the potential of this approach, but it was some years before key technical obstacles were overcome and the more widespread application of these therapies became possible. Whilst they were originally conceived as having an immunotherapeutic effect, it has become clear that recruitment of immune effectors is only one component of successful antibody therapy, and their action upon the cellular target, either blocking or agonistic, is also critical. The development of immunoconjugates to deliver toxins or radiation is a further extension of the approach, and here again the intracellular effect of antibody ligation appears to be crucial. This presentation will address the central theme of antibody treatments for malignancy that are now reaching the clinic, and will use these examples to highlight ways in which antibodies may be acting in vivo.
cancer, immunotherapy, lymphoma, monoclonal antibody
255-259
Johnson, P.W.M.
26932758-e8d4-4676-9e55-ed36d00665ea
Johnson, P.W.M.
26932758-e8d4-4676-9e55-ed36d00665ea

Johnson, P.W.M. (2001) The therapeutic use of antibodies for malignancy. Transfusion Clinique et Biologique, 8 (3), 255-259. (doi:10.1016/S1246-7820(01)00182-3).

Record type: Article

Abstract

The idea of using the specificity of antibodies to target malignant cells was put forward very soon after the discovery of techniques to generate monoclonal reagents. The responses seen with mouse anti-idiotype in patients with B-cell lymphomas indicated the potential of this approach, but it was some years before key technical obstacles were overcome and the more widespread application of these therapies became possible. Whilst they were originally conceived as having an immunotherapeutic effect, it has become clear that recruitment of immune effectors is only one component of successful antibody therapy, and their action upon the cellular target, either blocking or agonistic, is also critical. The development of immunoconjugates to deliver toxins or radiation is a further extension of the approach, and here again the intracellular effect of antibody ligation appears to be crucial. This presentation will address the central theme of antibody treatments for malignancy that are now reaching the clinic, and will use these examples to highlight ways in which antibodies may be acting in vivo.

This record has no associated files available for download.

More information

Published date: 2001
Keywords: cancer, immunotherapy, lymphoma, monoclonal antibody

Identifiers

Local EPrints ID: 26412
URI: http://eprints.soton.ac.uk/id/eprint/26412
PURE UUID: 63f2892c-17ee-4c56-bd46-b74282f4df6c

Catalogue record

Date deposited: 24 Apr 2006
Last modified: 15 Mar 2024 07:10

Export record

Altmetrics

Contributors

Author: P.W.M. Johnson

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×